News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In
WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMCs assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.
Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study, said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.
The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.
The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).
About ADG20ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.
About Adagio TherapeuticsAdagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The companys portfolio of antibodies has been optimized using Adimabs industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagios portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit http://www.adagiotx.com.
Contacts:Media Contact:Dan Budwick, 1ABDan@1abmedia.com
Investor Contact:Monique Allaire, THRUST Strategic Communicationsmonique@thrustsc.com
See the article here:
- Choosing Regular Food to Extend Longevity - CounterPunch.org - CounterPunch - April 18th, 2024 [April 18th, 2024]
- "I love the club, I'm really happy here" - Manchester United star opens up on life at club amid contract extension uncertainty - Sportskeeda - March 31st, 2023 [March 31st, 2023]
- Life Extension review - 7 facts you should know [APRIL 2022] - February 5th, 2023 [February 5th, 2023]
- Biomedical Research & Longevity Society - Wikipedia - January 27th, 2023 [January 27th, 2023]
- NAD+ Cell Regenerator and Resveratrol Elite - Life Extension - December 26th, 2022 [December 26th, 2022]
- FLORASSIST GI with Phage Technology - Life Extension - December 12th, 2022 [December 12th, 2022]
- Magnesium Citrate 100 mg, 100 capsules - Life Extension - November 5th, 2022 [November 5th, 2022]
- AMPK Metabolic Activator, 30 tablets - Life Extension - November 5th, 2022 [November 5th, 2022]
- Germany nuclear plants life extension approved by Cabinet - DW (English) - October 19th, 2022 [October 19th, 2022]
- Biohacking: What is it, types and hacks to try for beginners - Medical News Today - October 19th, 2022 [October 19th, 2022]
- 'Biggest day of my life': Kevin Porter Jr., Rockets react to extension - Rockets Wire - October 19th, 2022 [October 19th, 2022]
- Postharvest quality solution for tomatoes-on-the-vine - hortidaily.com - October 19th, 2022 [October 19th, 2022]
- JZZ Technologies, Inc. and Subsidiary LION Development Group, Enter into JV Agreement with affiliate of Hospitality Development Group, Inc. of Florida... - October 19th, 2022 [October 19th, 2022]
- 'I love the city': QB Zach Collaros inks 3-year contract extension to stay with Blue Bombers through 2025 - CBC.ca - October 19th, 2022 [October 19th, 2022]
- MSU-led team studying expansion of controlled environment culinary herb production across US - Michigan State University - October 19th, 2022 [October 19th, 2022]
- 60 seconds with...Wayne Dunn, Babcock International - Professional Engineering - October 19th, 2022 [October 19th, 2022]
- Wind energy operators must address these 5 areas to exploit the full value of monitoring - Windpower Engineering - October 19th, 2022 [October 19th, 2022]
- Extension shares tips for practicing fire safety in the fall - The Hartselle Enquirer - Hartselle Enquirer - October 19th, 2022 [October 19th, 2022]
- FIRST Robotics Prepares to Extend Its Reach to More Vermont Students - Seven Days - October 19th, 2022 [October 19th, 2022]
- Plant Life Cycles - Penn State Extension - October 2nd, 2022 [October 2nd, 2022]
- FDA Authorizes Shelf Life Extension for Certain Lots of Paxlovid - October 2nd, 2022 [October 2nd, 2022]
- EDF considers extending life of two UK nuclear plants due to energy crisis - The Guardian - October 2nd, 2022 [October 2nd, 2022]
- Rittenbach among Extension team professionals honored - Jamestown Sun | News, weather, sports from Jamestown North Dakota - The Jamestown Sun - October 2nd, 2022 [October 2nd, 2022]
- What is the circular economy and why is it essential for real sustainability? - Schroders - October 2nd, 2022 [October 2nd, 2022]
- 44 national and international NGOs call for renewal and expansion of truce in Yemen [EN/AR] - Yemen - ReliefWeb - October 2nd, 2022 [October 2nd, 2022]
- University City Townhomes residents now have until end of the year to find new low-income housing - The Philadelphia Inquirer - October 2nd, 2022 [October 2nd, 2022]
- New Eskom board: Business groups happy with mix of skills - News24 - October 2nd, 2022 [October 2nd, 2022]
- Full circle on the farm: Penn State alum returns to help educate Pa. growers - Pennsylvania State University - October 2nd, 2022 [October 2nd, 2022]
- Task Force: Blacks are owed hundreds of thousands - CalMatters - October 2nd, 2022 [October 2nd, 2022]
- ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director - GlobeNewswire - September 20th, 2022 [September 20th, 2022]
- Analysis: Behind Trump's media deal, a vote where only yes will do - Reuters - September 20th, 2022 [September 20th, 2022]
- Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 | Antibodies | News Channels - PipelineReview.com - September 20th, 2022 [September 20th, 2022]
- Action Hampshire get behind Sustainable Future Fund to reduce waste in business - Hampshire Chronicle - September 20th, 2022 [September 20th, 2022]
- Living the dream - Farm Progress - September 20th, 2022 [September 20th, 2022]
- Teck and Agnico Eagle Announce Agreement on the San Nicols Copper-Zinc Project located in Zacatecas, Mexico - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Most actively traded companies on the Toronto Stock Exchange - Winnipeg Free Press - September 20th, 2022 [September 20th, 2022]
- Giants Urged to Give Extension to 24-Year-Old Defender - Heavy.com - September 20th, 2022 [September 20th, 2022]
- Russias MiG-31 Fighter That Fired Hypersonic Missiles On Ukraine Conducted Drills In The Stratosphere - EurAsian Times - September 20th, 2022 [September 20th, 2022]
- Jaguar Mining Reports Confirmed Continuity of Mineralization at Pilar Gold Mine - Life of Mine Extension Drilling to Follow - Yahoo Finance - September 14th, 2022 [September 14th, 2022]
- Easy meals, life-saving knife skills part of West Texas Fair & Rodeo Spotlight Kitchen - Abilene Reporter-News - September 14th, 2022 [September 14th, 2022]
- Beyond Bulletproof: Why Billionaires Are Chasing Everlasting Health - Newsweek - September 14th, 2022 [September 14th, 2022]
- Did California Truly Extend the Life of Diablo Canyon? Only Time Will Tell. - JD Supra - September 14th, 2022 [September 14th, 2022]
- Youth Mental Health First Aid Trainings Offered This Fall - Iowa State University - September 14th, 2022 [September 14th, 2022]
- Finland to Extend Validity of Residence Permits for Ukrainian Refugees Under Temporary Protection - SchengenVisaInfo.com - SchengenVisaInfo.com - September 14th, 2022 [September 14th, 2022]
- Wildfire Smoke's Affect on Potato Crops Being Studied - University of Idaho - September 14th, 2022 [September 14th, 2022]
- National Weather Service Northern Indiana radar will be down beginning Monday for upgrades - WANE - September 7th, 2022 [September 7th, 2022]
- Renault Trucks Will Give New Life to Old Parts - Ward's Auto - September 7th, 2022 [September 7th, 2022]
- Stop the stigma and step in - Farm Progress - September 7th, 2022 [September 7th, 2022]
- Empire Wind and WCS Announce Extension of Historic Near Real-Time Acoustic Marine Monitoring Project In New York Bight - Business Wire - September 7th, 2022 [September 7th, 2022]
- Media Advisory: Chalk River Laboratories Officially Breaks Ground on One of the Largest Nuclear Research Facilities Ever Constructed in Canada -... - September 7th, 2022 [September 7th, 2022]
- PFAS pilot study gets yet another extension, scope and cost of another project reduced - wausaupilotandreview.com - September 7th, 2022 [September 7th, 2022]
- Predators extend deal with Bally Sports South - Awful Announcing - September 7th, 2022 [September 7th, 2022]
- WWYDW: Reactions to the Canucks' J.T. Miller extension - Canucks Army - September 7th, 2022 [September 7th, 2022]
- NASA's Artemis rocket makers explain that it's a marathon and a sprint - The Register - September 7th, 2022 [September 7th, 2022]
- Food supply chains are susceptible to fraud and adulteration more than ever, warns Kerry - Food Ingredients First - September 7th, 2022 [September 7th, 2022]
- Reprieve for The White Lady as iconic food truck gets 12-month licence extension - Stuff - September 7th, 2022 [September 7th, 2022]
- Gypsy Moth Biology & Life Cycle - University of Illinois Extension - August 30th, 2022 [August 30th, 2022]
- AgriLife's Johanna Hicks and Team Honored at 2022 National Health Outreach Conference - frontporchnewstexas.com - August 30th, 2022 [August 30th, 2022]
- Harmony Gold to maintain dividends despite facing two years of heavy capital bills - Miningmx - August 30th, 2022 [August 30th, 2022]
- Malaysian, Thai companies ink MOU to explore cooperation in Mechanised Infantry Fighting Vehicle life extension programme - The Edge Markets MY - August 30th, 2022 [August 30th, 2022]
- Coveris previews new packaging solutions targeting enhanced performance and recyclability - Packaging Europe - August 30th, 2022 [August 30th, 2022]
- KPF and heatherwick studio to extend singapore airport as cluster of lush 'neighborhoods' - Designboom - August 30th, 2022 [August 30th, 2022]
- Understanding Tax Liens. Could the IRS seize your car? - finehomesandliving.com - August 30th, 2022 [August 30th, 2022]
- Extension of Legacy Trail in Tyler to continue - Tyler Morning Telegraph - August 29th, 2022 [August 29th, 2022]
- KRUG: Extension learning opportunities around the corner - Hays Post - August 29th, 2022 [August 29th, 2022]
- Half-Life 2 VR is coming, here's how you can get it - Win.gg - August 29th, 2022 [August 29th, 2022]
- Transplant technology: United Therapeutics 3D-printing of human organs focused on every breath you take - Manchester Ink Link - August 29th, 2022 [August 29th, 2022]
- Serena Williams Interview on Leaving Tennis and Her Legacy - TIME - August 29th, 2022 [August 29th, 2022]
- Thousands of photos captured by everyday Australians reveal the secrets of our marine life as oceans warm - The Conversation - August 29th, 2022 [August 29th, 2022]
- Empathy and Solidarity: On Alejandro Varela's The Town of Babylon - lareviewofbooks - August 29th, 2022 [August 29th, 2022]
- How many people continue their stay in the UK or apply to stay permanently? - GOV.UK - August 29th, 2022 [August 29th, 2022]
- Anti-Aging Conference and Olympia Weekend Set for Back-to-Back Weekends in Vegas - Muscle & Fitness - August 15th, 2022 [August 15th, 2022]
- A son steps aboard the Eagle and into his father's world - Journal Inquirer - August 15th, 2022 [August 15th, 2022]
- Class to teach healthy living for those with chronic conditions - The Maryville Forum - August 15th, 2022 [August 15th, 2022]
- New application for disinfection of fresh-cut fruits by means ozone in the packaging - hortidaily.com - August 15th, 2022 [August 15th, 2022]
- Meatless Meats and Smokeless Smokes - Equities News - August 15th, 2022 [August 15th, 2022]
- Command & Control Success: Fireground Commander: Understanding the Impact - Firehouse - August 15th, 2022 [August 15th, 2022]
- Five Ways This Survey About Maine's Wellness is Absolutely Bogus - WJBQ - July 25th, 2022 [July 25th, 2022]
- Center for Advanced Innovation in Agriculture, Virginia Cooperative Extension help Virginia Tech showcase its land-grant mission at 2022 Virginia Ag... - July 25th, 2022 [July 25th, 2022]
- Anti-ageing tips: Here's how to rewind your biological clock - Hindustan Times - July 25th, 2022 [July 25th, 2022]